Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
Expert Rev Proteomics. 2014 Jun;11(3):285-302. doi: 10.1586/14789450.2014.899469. Epub 2014 Mar 20.
In the last decade, many proteomic technologies have been applied, with varying success, to the study of tissue samples of breast carcinoma for protein expression profiling in order to discover protein biomarkers/signatures suitable for: characterization and subtyping of tumors; early diagnosis, and both prognosis and prediction of outcome of chemotherapy. The purpose of this review is to critically appraise what has been achieved to date using proteomic technologies and to bring forward novel strategies - based on the analysis of clinically relevant samples - that promise to accelerate the translation of basic discoveries into the daily breast cancer clinical practice. In particular, we address major issues in experimental design by reviewing the strengths and weaknesses of current proteomic strategies in the context of the analysis of human breast tissue specimens.
在过去的十年中，许多蛋白质组学技术已被应用于乳腺癌组织样本的研究，以进行蛋白质表达谱分析，从而发现适合以下用途的蛋白质生物标志物/特征：肿瘤的特征和亚型分类；早期诊断，以及化疗的预后和预测。本综述的目的是批判性地评估迄今为止使用蛋白质组学技术所取得的成果，并提出基于临床相关样本分析的新策略，有望加速将基础发现转化为乳腺癌的日常临床实践。特别是，我们在分析人类乳腺组织标本的背景下，通过回顾当前蛋白质组学策略的优缺点，解决了实验设计中的主要问题。
